A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
| Autor: | Aimee Chappell, K. Martin Kortüm, Sarah Goldman-Mazur, Peter Barth, Rebecca Silbermann, Ariel Kleman, Sebastian Grosicki, Adam J. Olszewski, David Jayabalan, Julio Davila Valls, Irit Avivi, Daniel Coriu, Maria V. Mateos, Alessandro Gozzetti, Iwona Hus, Yael Cohen, Max Bittrich, Deepu Madduri, Julia Kelman, Stuart L. Goldberg, Gabor Mikala, Krzysztof Jamroziak, Chor S. Chim, Ruben Niesvizky, Saurabh Chhabra, Pawel Robak, Artur Jurczyszyn, Norbert Grząśko, Parameswaran Hari, Izabela Kozłowska, David H. Vesole, Massimo Gentile, Michel Delforge, Verónica González-Calle, Laura Rosiñol, Jorge J. Castillo, Monika Długosz-Danecka, Lidia Usnarska-Zubkiewicz, Anna Waszczuk-Gajda, Łukasz Szukalski, Jacek Czepiel, Jakub Radocha, Anna Suska |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Scoring system Adverse outcomes Female Humans Middle Aged Multiple Myeloma Progression-Free Survival Retrospective Studies Translocation Genetic Translocation Newly diagnosed 03 medical and health sciences 0302 clinical medicine Genetic Internal medicine Medicine Progression-free survival Multiple myeloma business.industry Retrospective cohort study Hematology medicine.disease Multicenter study 030220 oncology & carcinogenesis Cohort business 030215 immunology |
| Zdroj: | American journal of hematologyREFERENCES. 95(5) |
| ISSN: | 1096-8652 |
| Popis: | The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text